What is the recommended tapering schedule for discontinuing Ingrezza (valbenazine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Weaning off Ingrezza (valbenazine) should be done gradually under medical supervision, with a recommended tapering schedule of reducing the dose by 40 mg increments every 1-2 weeks, to minimize potential withdrawal symptoms or rebound effects. When discontinuing Ingrezza, it's essential to consider the medication's mechanism of action as a VMAT2 inhibitor, which affects dopamine regulation in the brain 1. The most recent and highest quality study on valbenazine, published in 2019, highlights the importance of gradual discontinuation to avoid worsening of tardive dyskinesia symptoms 2.

Some key points to consider when tapering off Ingrezza include:

  • Reducing the dose by 40 mg increments every 1-2 weeks, for example, decreasing from 80 mg daily to 40 mg daily for 1-2 weeks before stopping completely 1
  • Monitoring for any changes in movement symptoms and reporting these to the healthcare provider 2
  • Individual factors such as duration of treatment, dose, and symptom severity will influence the specific tapering schedule, so it's crucial to follow the doctor's personalized recommendations 3
  • Although the provided evidence does not directly address the tapering schedule for Ingrezza, the general principle of gradual tapering to minimize withdrawal symptoms is supported by studies on other medications, such as SSRIs 4

It's essential to note that abrupt discontinuation of Ingrezza may lead to worsening of tardive dyskinesia symptoms, and the need for gradual discontinuation is based on the medication's mechanism of action as a VMAT2 inhibitor, which affects dopamine regulation in the brain 1, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.